ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million ...

Learn more Celebrations may be in order for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company.

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ ...

Pre-clinical pipeline expanded with novel wholly-owned candidates PN-477, an oral and s.c. triple GLP-GIP-GCG agonist and PN-458, an oral and s.c. dual GLP-GIP agonist, and PN-8047, an oral hepcidin ...

Vanessa Traina, stylist for Balenciaga and Altuzarra, and Morgan Wendelborn, formerly of Shopbop.com, are hitting the online retail space with theline.com, an e-commerce "experience" that offers home, ...

This article contains Tenet spoilers. The Protagonist might be one of the most unimaginatively named main characters of all time, but it’s worth pointing out that he is referred to as “the Protagonist ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...

London-based sales, finance and production company Protagonist Pictures has launched a boutique label on the eve of Cannes. Announced by Protagonist CEO Dave Bishop, Protagonist Picks will be led by ...